



July 15, 2011

TO: Pesticide Registration and Evaluation Committee

SUBJECT: PRIORITIZATION AND STATUS OF ACTIVE INGREDIENTS FOR RISK CHARACTERIZATION: REPORT # 52

The Birth Defect Prevention Act of 1984 (SB 950) requires the California Department of Pesticide Regulation (DPR) to review the toxicology data for all active ingredients currently registered in California.

As part of this review, the active ingredients listed on the attached list were identified as having potential adverse health effects in studies of sufficient quality to permit risk characterization. As a result, these active ingredients will enter the risk characterization process. During this process, DPR staff will identify the seriousness of the adverse effect, determine the expected levels of human exposure, assess the resulting risk to human health, and, if necessary, explore possible mitigation measures.

The results of this risk characterization process will help DPR staff determine if any registration action is warranted. A registration action is not the automatic result for every active ingredient entering the risk characterization process. In addition, as data gaps are filled, other adverse effects might be identified, necessitating another risk characterization. Finally, the risk characterization process should be viewed as a comprehensive evaluation requiring, in some cases, a considerable amount of time. Therefore, it is not possible to predict how long it will take to systematically complete the risk characterization process for each priority category.

The risk characterization document is forwarded to the Assistant Director for approval. When the risk characterization process has been completed, the active ingredient will be removed from this list. Any subsequent risk management activities will be conducted under a separate DPR process.

Attached is a list of active ingredients and the type of corresponding study in which the potential adverse health effects were noted. The active ingredients have been prioritized into High, Moderate, and Low categories.

The prioritization of the active ingredients is a subjective process based upon the nature of potential adverse effect, the number of potential adverse effects, the number of species affected, the no observable effect level (NOEL), potential human exposure, use patterns, quantity used, EPA evaluations and actions, etc. In addition, the status of the active ingredients in risk



Pesticide Registration and Evaluation Committee  
July 15, 2011  
Page 2

characterization under Senate Bill 950 (Birth Defects Prevention Act), Assembly Bill (AB) 1807 (Toxic Air Contaminant Act), AB 2161 (Food Safety Act), Proposition 65, and new registration submissions are provided in this report.

Questions about the information contained in this report can be directed to Dr. Jay Schreider, Primary State Toxicologist in the Medical Toxicology Branch, at (916) 445-4241, or by e-mail at <[jschreider@cdpr.ca.gov](mailto:jschreider@cdpr.ca.gov)>.

Sincerely,

*Original signed by*

Gary Patterson, Ph.D., Chief  
Medical Toxicology Branch  
(916) 324-3466

Attachment

cc: Dr. Jay Schreider, Primary State Toxicologist

## RISK ASSESSMENT PRIORITIZATION LIST

Report # 52

July 15, 2011

The following is a list of the active ingredients that will undergo or are undergoing a risk assessment. The active ingredients have been prioritized into High, Moderate and Low categories. Also listed is the type of toxicity study in which the possible adverse effect(s) was noted.

<u>Active Ingredient</u>	<u>Studies Indicating Possible Adverse Effects</u>
<b>High Priority</b>	
1. Acephate	Genotoxicity study, oncogenicity study, chronic toxicity study, low NOEL
2. Acrolein	Genotoxicity study, chronic toxicity study, oncogenicity study, reproduction study
3. Aldicarb	Low NOEL
4. Arsenic, inorganic	Oncogenicity study (epidemiology), neurotoxicity (epidemiology), genotoxicity study, teratology study
5. Azafenidin	Chronic toxicity study, oncogenicity study, teratology study, reproduction study
6. Bromoxynil	Genotoxicity study, oncogenicity study, teratology study
7. Captan	Genotoxicity study, oncogenicity study
8. Carbaryl	Genotoxicity study, oncogenicity study
9. Chloropicrin	Genotoxicity study, teratology study
10. Chlorothalonil	Combined oncogenicity/chronic toxicity study, oncogenicity study, genotoxicity study
11. Chlorpyrifos	Genotoxicity study, reproduction study
12. <i>Cyflufenamid*</i>	<i>Oncogenicity</i>
13. Cyfluthrin	Teratology study, reproduction study
14. $\lambda$ -Cyhalothrin (lambda form)	Chronic toxicity study, oncogenicity study

*Changes from previous Report #51 (7/16/2009) are in italics*

\* new active ingredient

## RISK ASSESSMENT PRIORITIZATION LIST

Report # 52

July 15, 2011

15.	2,4-D	Combined oncogenicity/chronic toxicity study, reproduction study, genotoxicity study
16.	Daminozide	Oncogenicity study
17.	Dazomet	Chronic toxicity study, teratology study, genotoxicity study
18.	Diazinon	Genotoxicity study, reproduction study
19.	Dicamba	Neurotoxicity study, chronic toxicity study, oncogenicity study
20.	Dichlobenil	Combined oncogenicity/chronic toxicity study
21.	1,3-Dichloropropene (Telone)	Systemic toxicity/short term exposure
22.	Dicofol	Oncogenicity study, low NOEL, reproduction study
23.	Dimethoate	Genotoxicity study, low NOEL
24.	<i>Dimethyl Disulfide*</i>	<i>Oncogenicity Study</i>
25.	Disulfoton	Genotoxicity, low NOELs
26.	Emamectin Benzoate	Neurotoxicity in subchronic and chronic studies, reproduction study
27.	Ethylene oxide	Combined oncogenicity/chronic toxicity study, oncogenicity study, genotoxicity study
28.	Ethylene thiourea (ETU)	Genotoxicity study, chronic toxicity study, combined oncogenicity/chronic toxicity study
29.	Famoxadone	Chronic toxicity study; genotoxicity study
30.	Fenamiphos	Genotoxicity study, low NOEL
31.	Fenbuconazole	Chronic toxicity study, oncogenicity study, combined oncogenicity/chronic toxicity study, reproduction study, teratology study

*Changes from previous Report #51 (7/16/2009) are in italics*

\* new active ingredient

## RISK ASSESSMENT PRIORITIZATION LIST

Report # 52

July 15, 2011

32.	Fenvalerate/Esfenvalerate	Neurotoxicity
33.	Fipronil	Chronic toxicity study, combined chronic toxicity/oncogenicity study
34.	<i>Fluazinam*</i>	<i>Oncogenicity, developmental toxicity, neurotoxicity</i>
35.	<i>Fluopyram*</i>	<i>Oncogenicity</i>
36.	Flonicamid	Oncogenicity
37.	Flumioxazin	Chronic toxicity study, reproduction study, teratology study
38.	<i>Fosthiazate *</i>	<i>Cholinesterase inhibition, reproduction, Neurotoxicity</i>
39.	Glufosinate ammonium	Chronic toxicity study, teratology study
40.	Glutaraldehyde	Genotoxicity study, subchronic toxicity study, combined toxicity study
41.	Imazalil	Teratology study
42.	Indoxacarb	Subchronic toxicity studies, combined chronic toxicity/oncogenicity study, chronic toxicity study, oncogenicity study, neurotoxicity study
43.	Iprodione	Genotoxicity study, chronic toxicity studies, oncogenicity study
44.	Linuron	Combined oncogenicity/chronic toxicity study, oncogenicity study, chronic toxicity study, reproduction study
45.	Mancozeb	Genotoxicity study, chronic toxicity study (also see ETU)
46.	<i>Metconazole*</i>	<i>Chronic toxicity, oncogenicity, genotoxicity, reproduction</i>

*Changes from previous Report #51 (7/16/2009) are in italics*

\* new active ingredient

## RISK ASSESSMENT PRIORITIZATION LIST

Report # 52

July 15, 2011

47.	Methiocarb	Teratology study
48.	Methyl parathion	Reproduction study, teratology study, genotoxicity study, chronic toxicity study
49.	Metofluthrin	Oncogenicity, neurotoxicity
50.	Milbemectin	Reproduction study, neurotoxicity study, subchronic toxicity study
51.	N-octylbicycloheptene dicarbomixide (MGK-264)	Oncogenicity study
52.	Novaluron	Chronic toxicity
53.	Orthophenylphenol	Genotoxicity study, oncogenicity study, teratology study
54.	Oxadiazon	Chronic toxicity study, oncogenicity study, genotoxicity study, teratology study
55.	Oxydemeton-methyl	Reproduction study, genotoxicity study
56.	Paradichlorobenzene	Oncogenicity study, reproduction study, genotoxicity study
57.	Paraquat dichloride	Genotoxicity study, oncogenicity study, combined oncogenicity/chronic toxicity study, chronic toxicity study
58.	PCNB	Genotoxicity study, oncogenicity studies
59.	Profenofos	Low NOEL, chronic toxicity study
60.	Propanil	Combined oncogenicity/chronic toxicity study, chronic toxicity study, oncogenicity study
61.	Propargite	Reproduction study, genotoxicity study, combined oncogenicity/chronic toxicity study
62.	Propylene oxide	Genotoxicity study, oncogenicity study
63.	Propyzamide	Oncogenicity study

*Changes from previous Report #51 (7/16/2009) are in italics*

\* new active ingredient

## RISK ASSESSMENT PRIORITIZATION LIST

Report # 52

July 15, 2011

64.	<i>Prothiconazole*</i>	<i>Chronic toxicity, developmental toxicity</i>
65.	Pyraclostrobin	Subchronic toxicity study, low NOEL's in teratology, chronic and reproduction studies
66.	Sodium tetrathiocarbonate (CS <sub>2</sub> )	Multiple toxicity studies
67.	Spirodiclofen	Chronic dog, rat and mouse oncogenicity, Rat reproduction
68.	Spiromesifin	Low NOELs
69.	Spirotetramat	Chronic and oncogenicity
70.	Sulfentrazone	Chronic rat, reproductive effects, rat Developmental toxicity
71.	Tebuconazole	Teratology study
72.	Thiacloprid	Oncogenicity, reproductive toxicity
73.	<i>Thiamethoxam*</i>	Oncogenicity, chronic toxicity
74.	Thiazopyr	Subchronic toxicity study, combined oncogenicity /chronic toxicity study
75.	Thiophanate-methyl	Oncogenicity studies, chronic toxicity studies
76.	Tralkoxydim	Chronic toxicity study, combined toxicity study, teratology study
77.	Triadimefon	Teratology study, oncogenicity study, reproduction study, chronic toxicity study
78.	Triallate	Oncogenicity study, chronic toxicity study, genotoxicity study
79.	Tributyltin benzoate	Developmental toxicity study, oncogenicity study
80.	Trifloxysulfuron-sodium	Neurotoxicity study

*Changes from previous Report #51 (7/16/2009) are in italics*

\* new active ingredient

## RISK ASSESSMENT PRIORITIZATION LIST

Report # 52

July 15, 2011

- |     |             |  |
|-----|-------------|--|
| 81. | Vinclozolin | Chronic toxicity study, teratology study, genotoxicity study, reproduction study |
| 82. | Ziram       | Oncogenicity study, reproduction study, genotoxicity study                       |

### **Moderate Priority**

- |     |  |   |
|-----|--|---|
| 1.  | Acequinocyl                            | Chronic toxicity study, reproduction study  |
| 2.  | Acetamiprid                            | Subchronic and chronic toxicity studies   |
| 3.  | Acibenzolar-s-methyl                   | Combined chronic toxicity/oncogenicity study, teratology study, genotoxicity study, chronic toxicity study, subchronic toxicity study |
| 4.  | Alkyldimethyl benzyl ammonium chloride | Teratology study  |
| 5.  | Azoxystrobin                           | Teratology study  |
| 6.  | Bensulide                              | Chronic toxicity study, low NOEL, delayed neurotoxicity study   |
| 7.  | Bentazon, sodium salt                  | Teratology study, oncogenicity study  |
| 8.  | Bifenazate                             | Chronic toxicity study, combined toxicity study   |
| 9.  | Boric acid                             | Chronic toxicity study, teratology study  |
| 10. | Boscalid (BAS510F)                     | Oncogenicity study  |
| 11. | Bromacil                               | Oncogenicity study, genotoxicity study  |
| 12. | Buprofezin                             | Subchronic toxicity study, chronic toxicity study, combined toxicity study, teratology study  |
| 13. | Cacodylic acid                         | Genotoxicity study, chronic toxicity study, oncogenicity study, teratology study  |
| 14. | Carboxin                               | Genotoxicity, oncogenicity, chronic toxicity  |

*Changes from previous Report #51 (7/16/2009) are in italics*

\* new active ingredient

## RISK ASSESSMENT PRIORITIZATION LIST

Report # 52

July 15, 2011

15.	Chlorflurenol, methyl ester	Chronic toxicity study, teratology study
16.	Chlorthal-dimethyl	Combined oncogenicity/chronic toxicity study, oncogenicity study
17.	Clomazone	Chronic toxicity study, teratology study
18.	Clothianidin	Genotoxicity, neurotoxicity (subchronic study)
19.	Coumaphos	Cholinesterase inhibition, neurotoxicity
20.	Cryolite	Oncogenicity study
21.	<i>Cumyluron*</i>	<i>Genotoxicity</i>
22.	Cyanuric acid, monosodium salt	Combined oncogenicity/chronic toxicity study
23.	Cyclanilide	Combined oncogenicity/chronic toxicity study
24.	Cymoxanil	Genotoxicity study, chronic toxicity study, teratology study
25.	Cypermethrin	Chronic toxicity studies, oncogenicity study, reproduction study
26.	Cyphenothrin	Neurotoxicity
27.	Cyprodinil	Subchronic toxicity study, combined oncogenicity/chronic toxicity study
28.	2,4-DB [4-(2,4-dichloro-phenoxy)butyric acid]	Genotoxicity studies, reproduction study
29.	<i>2,2-Dibromo-3-nitrilo-Propionamide</i>	<i>Developmental toxicity</i>
30.	Dichloran/Dicloran	Genotoxicity study, chronic toxicity study, reproduction study
31.	Didecyldimethyl-ammonium chloride	Low NOEL

*Changes from previous Report #51 (7/16/2009) are in italics*

\* new active ingredient

## RISK ASSESSMENT PRIORITIZATION LIST

Report # 52

July 15, 2011

32.	N,N-Diethyl-2-(4-methylbenzyloxy)-ethylamine Hydrochloride (PT807-HCL)	Subchronic toxicity study, chronic toxicity
33.	Difenacoum	Genotoxicity, chronic effects
34.	Difenoconazole	Teratology studies, combined oncogenicity/chronic toxicity study
35.	Difethialone	Low NOEL (acute, subchronic)
36.	Dimethenamid-P	Rat oncogenicity/chronic toxicity, low NOEL
37.	Dimethomorph	Oncogenicity study, chronic toxicity study, genotoxicity study
38.	O,O-Dimethyl O-(4-nitro-M-tolyl)-phosphorothioate (Sumithion)	Low NOEL (subchronic study), oncogenicity study, reproduction study
39.	Dinotefuran	Reproduction study, chronic toxicity study, subchronic toxicity study
40.	Diphenylamine	ombined chronic toxicity/oncogenicity study
41.	Dipropyl iso-cinchomeronate (MGK-326)	Oncogenicity studies
42.	Dithiopyr	Subchronic toxicity studies
43.	Diuron	Genotoxicity study, oncogenicity studies
44.	Dodine	Oncogenicity study
45.	Endothall	Chronic toxicity study, oncogenicity study
46.	Esbiothrin	Genotoxicity study, reproduction study
47.	Ethalfuralin	Chronic toxicity study, genotoxicity study, combined oncogenicity/chronic toxicity study
48.	Ethofumesate	Teratology study

*Changes from previous Report #51 (7/16/2009) are in italics*

\* new active ingredient

## RISK ASSESSMENT PRIORITIZATION LIST

Report # 52

July 15, 2011

49.	Etoxazole	Genotoxicity study
50.	Fenarimol	Combined oncogenicity/chronic toxicity
51.	<i>Flazasulfuron*</i>	<i>Chronic toxicity, developmental toxicity</i>
52.	Flubendiamide	Chronic effects in multiple studies
53.	Fludioxonil	Combined oncogenicity/chronic toxicity study, subchronic toxicity study
54.	Fluopicolide	Oncogenicity and liver changes
55.	Fluoxastrobin	Oncogenicity
56.	Fluroxypyr	Chronic toxicity study, subchronic toxicity study
57.	Flurprimidol	Chronic toxicity study, teratology study, reproduction study
58.	<i>Flutriafol*</i>	<i>Oncogenicity, developmental and neurotoxicity</i>
59.	$\tau$ -Fluvalinate (tau form)	Genotoxicity study, reproduction study, teratology study, chronic toxicity study
60.	Forchlorfenuron	Genotoxicity study
61.	Formaldehyde	Genotoxicity study, oncogenicity study
62.	Halosulfuron-methyl	Chronic toxicity study
63.	Hexahydro-1,3,5-triethyl-S-triazine	Teratology study
64.	Hexythiazox	Oncogenicity study
65.	(Hydroxymethyl)phosphonium sulfate (Tetrakis)	Teratology Study
66.	Imidacloprid	Combined oncogenicity/chronic toxicity study, teratology study, genotoxicity study
67.	Imiprothrin	Teratology study, neurotoxicity study, chronic toxicity study, genotoxicity study

*Changes from previous Report #51 (7/16/2009) are in italics*

\* new active ingredient

## RISK ASSESSMENT PRIORITIZATION LIST

Report # 52

July 15, 2011

68.	<i>Indaziflam*</i>	<i>Chronic toxicity in several species, neurotoxicity, genotoxicity</i>
69.	<i>Ipconazole*</i>	<i>Reduced body weight in several species</i>
70.	Isoxaben	Oncogenicity studies, genotoxicity study.
71.	Kresoxim-methyl	Combined chronic toxicity/oncogenicity study
72.	Mandipropamid	Organ and body weight effects
73.	MCPA	Genotoxicity study
74.	Mecoprop (MCP)	Oncogenicity study, genotoxicity study
75.	Mefenoxam	Genotoxicity study
76.	Mefluidide, diethanolamine salt	Combined oncogenicity/chronic toxicity study, oncogenicity study, chronic toxicity study
77.	Metaflumizone	Genotoxicity
78.	Metalaxyl	Genotoxicity study
79.	Methomyl	Oncogenicity study, chronic toxicity study
80.	Methoxyfenozide	Chronic toxicity study, combined toxicity study, reproduction study
81.	<i>Metrafenone*</i>	<i>Oncogenicity</i>
82.	Metribuzin	Chronic toxicity study
83.	MSMA/MAA	Combined oncogenicity/chronic toxicity study
84.	Napropamide	Combined oncogenicity/chronic toxicity study, genotoxicity study
85.	Napthalene acetic acid	Reproduction study, teratology study, chronic toxicity study, combined toxicity study

*Changes from previous Report #51 (7/16/2009) are in italics*

\* new active ingredient

## RISK ASSESSMENT PRIORITIZATION LIST

Report # 52

July 15, 2011

88.	Norflurazon	Chronic toxicity study
89.	Noviflumuron (XDE-007)	Reproduction study
90.	Ortho-benzyl-para-chlorophenol	Teratology study
91.	Oryzalin	Oncogenicity study, chronic toxicity study
92.	Oxyfluorfen	Genotoxicity study, oncogenicity study, teratology study
93.	Oxythioquinox	Chronic toxicity study, reproduction study, teratology study, genotoxicity study
94.	Pebulate	Combined oncogenicity/chronic toxicity study, chronic toxicity study
95.	Penoxsulam	Oncogenicity
96.	Permethrin	Reproduction study, chronic toxicity study, oncogenicity study
97.	Phenol	Oncogenicity studies
98.	Phenothrin	Oncogenicity study, reproduction toxicity study
99.	Phorate	Low NOEL
100.	Picaridin (KBR 3023)	Subchronic toxicity, genotoxicity
101.	Picloram	Combined chronic toxicity/oncogenicity study
102.	Pinoxaden	Genotoxicity
103.	Polyhexamethylene biguanidine (Baquacil)	Teratology study
104.	<i>Polymeric betaine</i>	<i>Subchronic toxicity</i>
105.	Prallethrin (ETOC)	Subchronic toxicity study, chronic toxicity study, teratology study

*Changes from previous Report #51 (7/16/2009) are in italics*

\* new active ingredient

## RISK ASSESSMENT PRIORITIZATION LIST

Report # 52

July 15, 2011

106	Prometon	Low NOEL
107.	Propiconazole	Low NOEL, chronic toxicity study
108.	Pymetrozine	Combined oncogenicity/chronic toxicity study, oncogenicity study, acute neurotoxicity study
109.	Pyraflufen-ethyl	Chronic toxicity study, oncogenicity study, genotoxicity study
110.	Pyrethrins	Reproduction study, genotoxicity study, oncogenicity study
111.	Pyridaben	Low NOEL
112.	<i>Pyridalyl</i>	<i>Oncogenicity, genotoxicity</i>
113.	Pyridate	Chronic toxicity study
114.	Pyrimethanil	Oncogenicity
115.	Pyriproxyfen	Chronic toxicity study
116.	Pyrithiobac-sodium	Combined chronic toxicity/oncogenicity study
117.	Quinclorac	Chronic toxicity study; genotoxicity study
118.	Resmethrin	Teratology study, oncogenicity study, chronic toxicity study, reproduction study
119	Rimsulfuron	Chronic toxicity studies
120.	Saflufenacil	Genotoxicity (also, anemia)
121.	Simazine	Combined oncogenicity/chronic toxicity study
122.	Spinetoram	Chronic toxicity
123.	Spinosad	Chronic toxicity study, combined chronic toxicity/oncogenicity study

*Changes from previous Report #51 (7/16/2009) are in italics*

\* new active ingredient

## RISK ASSESSMENT PRIORITIZATION LIST

Report # 52

July 15, 2011

124.	Sulfosulfuron	Chronic toxicity, oncogenicity
125.	TCMTB	Oncogenicity study
126.	Tebufenozide	Chronic toxicity studies
127.	Terbuthylazine (Bellacide)	Low NOEL
128.	Tetrachlorvinphos	Oncogenicity study, genotoxicity study
129.	Tetraconazole	Oncogenicity (sugarbeets only use)
130.	Thiodicarb	Oncogenicity study, reproduction study, genotoxicity study
131.	Thiram	Low NOEL, teratology study, chronic toxicity study, combined oncogenicity/chronic toxicity study
132.	Tribenuron-methyl	Reproduction study
133.	Trichlorfon	Combined chronic toxicity/oncogenicity study, genotoxicity study
134.	Triclopyr	Genotoxicity study, low NOEL
135.	Trifloxystrobin	Oncogenicity study, chronic toxicity study, genotoxicity study
136.	Triflumizole	Chronic toxicity study
137.	Trifluralin	Combined oncogenicity/chronic toxicity study, oncogenicity study
138.	Triforine	Teratology study, oncogenicity study
139.	Tris (hydroxymethyl nitromethane)	Genotoxicity study, teratology study
140.	Triflusulfuron-methyl	Chronic toxicity study, oncogenicity study
141.	Triticonazole	Chronic dog (eye effects); genotoxicity

*Changes from previous Report #51 (7/16/2009) are in italics*

\* new active ingredient

## RISK ASSESSMENT PRIORITIZATION LIST

Report # 52

July 15, 2011

- |      |  |  |
|------|--|--|
| 142. | Uniconazole-P                                      | Chronic toxicity study, oncogenicity study, genotoxicity study, low NOEL |
| 143. | Zinc 2-Pyridinethiol-1-oxide<br>( <i>omadine</i> ) | Teratology studies   |

### Low Priority

- |     |   |  |
|-----|---|--|
| 1.  | Alachlor  | Oncogenicity study, chronic toxicity study, low NOEL |
| 2.  | Alpha-isoctadecyl-omega-hydroxy-poly(oxyethylene) | None identified                                      |
| 3.  | <i>Ametoctradin*</i>                              | <i>None identified</i>                               |
| 4.  | <i>Aminocyclopyrchlor*</i>                        | <i>Reproductive toxicity</i>                         |
| 5.  | Aminopyralid                                      | Chromosome aberrations                               |
| 6.  | 4-t-Amylphenol (Para-tert-amylphenol)             | None identified                                      |
| 7.  | Azadirachten                                      | None identified                                      |
| 8.  | Bacillus subtilis                                 | None identified                                      |
| 9.  | Bacillus thuringiensis                            | None identified                                      |
| 10. | Beauveria bassiana                                | None identified                                      |
| 11. | Benefin   | Combined chronic toxicity/oncogenicity study         |
| 12. | Benzyl benzoate                                   | None identified                                      |
| 13. | Bronopol  | Chronic toxicity study, low NOEL                     |
| 14. | Butylate  | Genotoxicity study, neurotoxicity study              |
| 15. | N-Butyl-1,2-benzisothiazole-3-one                 | Genotoxicity   |
| 16. | Carfentrazone-ethyl                               | Chronic toxicity studies                             |
| 17. | Chlorhexidine diacetate                           | Dermal (local) effects                               |

*Changes from previous Report #51 (7/16/2009) are in italics*

\* new active ingredient

## RISK ASSESSMENT PRIORITIZATION LIST

Report # 52

July 15, 2011

18.	1-(3-Chloroallyl)-3,5,7-triazazoniaadamantane	Genotoxicity study, teratology study
19.	4-Chloro-3,5-xyleneol	Genotoxicity study
20.	Chlorpropham	Genotoxicity study
21.	Chlorsulfuron	Chronic toxicity study
22.	Clethodim	Genotoxicity study
23.	Clopyralid	Subchronic toxicity study; combined oncogenicity/chronic toxicity study
24.	Copper 2-pyridinethiol-oxide (Omadine)	Neurotoxicity
25.	Cyazofamid	Body and organ weight effects
26.	N-Cyclopropyl-N'-(1,1-dimethylethyl)-6-(methylthio)-1,3,5-triazine-2,4-diamine (Irgarol)	None identified
27.	2,4-DP	Combined oncogenicity/chronic toxicity study
28.	Desmedipham	Genotoxicity study, teratology study
29.	1,2-Dibromo-2,4-dicyanobutane (Tektamer 38)	Subchronic toxicity study
30.	4,5-Dichloro-2-noctyl-3(2H)-isothiazolone (Sea-Nine)	Antimicrobial; local corrosive effects
31.	Dichlorprop-p	Chronic toxicity studies
32.	Difenzoquat methyl sulfate	Chronic toxicity study
33.	Diflufenzopyr	Teratology study, reproduction study
34.	Dimethipin	Chronic toxicity study
35.	Dimethoxane	Oncogenicity study, genotoxicity study

*Changes from previous Report #51 (7/16/2009) are in italics*

\* new active ingredient

## RISK ASSESSMENT PRIORITIZATION LIST

Report # 52

July 15, 2011

36.	5,5-Dimethylhydantoin	Chronic toxicity studies
37.	4,4-Dimethyloxazolidine	Genotoxicity study
38.	Ethephon	Genotoxicity study
39.	Fenamidone	Chronic toxicity studies, genotoxicity studies
40.	Fenhexamid	Subchronic and chronic toxicity studies
41.	Flumiclorac-pentyl	Chromosome aberrations
42.	Fluridone	Chronic toxicity study, oncogenicity study
43.	Flutolonil	Genotoxicity study, combined oncogenicity/ chronic toxicity study
44.	Foramsulfuron	Genotoxicity study
45.	Formetanate hydrochloride	Genotoxicity study
46.	Fosetyl-Al	Combined oncogenicity/chronic toxicity study
47.	Gliocladium virens	None identified
48.	Glyphosate	Oncogenicity studies
49.	Halofenozide	Teratology study, subchronic toxicity study
50.	Hexazinone	Genotoxicity study
51.	Hydroprene	Chronic toxicity study, oncogenicity study
52.	5-Hydroxymethyl-1-aza-3,7-dioxabicyclo-(3,3,0)octane	Genotoxicity study
53.	Imazamethabenz	Subchronic toxicity, chronic toxicity/ oncogenicity

*Changes from previous Report #51 (7/16/2009) are in italics*

\* new active ingredient

## RISK ASSESSMENT PRIORITIZATION LIST

Report # 52

July 15, 2011

54.	Imazamox, ammonium salt	Teratology studies
55.	Imazapic	Chronic toxicity study
56.	Imazapyr	Teratology study
57.	Imazethapyr	Genotoxicity study, teratology study
58.	<i>Imazosulfuron*</i>	<i>Chronic toxicity</i>
59.	Intersept (for chemical details, see chemicals 3836, 3837, 3838)	Teratology study
60.	Maleic hydrazide	Genotoxicity study
61.	Maneb (also see ETU-High Priority)	Genotoxicity study
62.	Mepiquat chloride	Chronic toxicity studies
63.	Mesosulfuron-methyl	Subchronic toxicity study
64.	Metaldehyde	Chronic toxicity study
65.	Methylene bis(thiocyanate)	Genotoxicity study
66.	Metolachlor	Oncogenicity study, chronic toxicity study
67.	<i>N,N-Methylenebis-Morpholine*</i>	<i>Genotoxicity</i>
68.	Nicosulfuron (Accent)	None identified
69.	Nithiazine	Neurotoxicity study
70.	Nitrapyrin	Combined oncogenicity/chronic toxicity study
71.	4-(2-Nitrobutyl) morpholine/ 4,4'-(2-ethyl-2-nitrotrimethylene) morpholine	Genotoxicity study
72.	Octhilinone	Genotoxicity study
73.	Orthosulfamuron	Oncogenicity and chronic liver changes
74.	Oxamyl	Chronic toxicity study

*Changes from previous Report #51 (7/16/2009) are in italics*

\* new active ingredient

## RISK ASSESSMENT PRIORITIZATION LIST

Report # 52

July 15, 2011

75.	Oxazolidine E (Bioban)	Teratology study
76.	Parachlorometacresol	Antimicrobial; local irritant
77.	Pendimethalin	Oncogenicity study
78.	Phenmedipham	None identified; incomplete data base
79.	Piperonyl butoxide	Oncogenicity study
80.	Prodiamine	Teratology study, genotoxicity study
81.	Prohexadione calcium	Chronic toxicity study, genotoxicity study
82.	Prometryn	None identified
83.	Propoxycarbazone-sodium	None identified
84.	Pseudomonas cepacia (Blue Circle)	None identified
85.	Pseudomonas fluorescens (Frostban A&B)	None identified
86.	Pseudomonas syringae	None identified
87.	Pyrazon	Chronic toxicity studies
88.	Rotenone	Genotoxicity study
89.	Sethoxydim	Teratology study, chronic toxicity study
90.	Siduron	Oncogenicity study
91.	Sodium hydroxymethyl glycinate	None identified
92.	Streptomyces griseoviridis (Mycostop)	None identified
93.	Tebuthiuron	Reproduction study, teratology study, mutagenicity study
94.	Tetramethrin	Reproduction study, oncogenicity study, teratology study

*Changes from previous Report #51 (7/16/2009) are in italics*

\* new active ingredient

## RISK ASSESSMENT PRIORITIZATION LIST

Report # 52

July 15, 2011

95.	Thiobencarb	Genotoxicity study
96.	Tralopyril	Antifouling paint
97.	<i>Tributyl tetradecyl phosphonium chloride</i>	<i>Antimicrobial</i>
98.	Trinexapac-ethyl (Cimectacarb)	Combined oncogenicity/chronic toxicity

### CHANGES TO THE RISK ASSESSMENT PRIORITIZATION LIST

#### A. Changes in Status of Active Ingredients Already on Prioritization List

#### B. Active Ingredients Removed from Prioritization List <sup>a</sup> (1)

*Methyl iodide*

a/ A completed risk assessment must be approved by Assistant Director before it can be removed from the PREC prioritization list

#### C. Active Ingredients Added to Prioritization List (4)

*Amentocradin\**

*Aminocyclopyrchlor\**

*Cumyluron\**

*Cyflufenamid\**

*Dimethyl Disulfide\**

*Flazasulfuron\**

*Fluazinam\**

*Fluopyram\**

*Flutriafol\**

*Fosthiazate\**

*Imazosulfuron\**

*Indaziflam*

*N,N-Methylenebis-Morpholine\**

*Metconazole\**

*Metrafenone\**

*Polymeric betaine\**

*Prothioconazole\**

*Pyridaly\**

*Tributyl tetradecyl phosphonium chloride\**

### STATUS OF ACTIVE INGREDIENTS CURRENTLY IN RISK ASSESSMENT

Changes from previous Report #51 (7/16/2009) are in italics

\* new active ingredient

## RISK ASSESSMENT PRIORITIZATION LIST

Report # 52

July 15, 2011

*Note: The following list only includes those active ingredients that are currently in risk assessment. It does not include the active ingredients in risk mitigation/risk management. Once the risk assessment for a specific active ingredient has been completed and approved by the Assistant Director, that active ingredient is removed from the SB-950/PREC Prioritization List. In addition to conducting a risk assessment under SB-950 for occupational and residential exposures, many risk assessments contain a dietary component under AB-2161 and an air component under AB-1807. Whenever possible, these components are included in one, comprehensive risk characterization document.*

The following stages of the risk assessment process are included in this status section:

**Hazard Identification Stage:** includes the development of the Toxicology Profile Section and the selection of the definitive studies, critical endpoints and NOEL/LOEL/oncogenicity potency values that will be used for risk characterization. Responsibility: Medical Toxicology Branch.

**Exposure Assessment Stage:** includes the development of occupational, residential, dietary (food/water), ambient air and off-site air exposure scenarios. Responsibility: Worker Health and Safety Branch for occupational, residential and air. Medical Toxicology Branch for dietary.

**Risk Characterization Stage:** includes the development of quantitative values used to assess the risk from critical NOELs/oncogenic potency factors and exposure values. Responsibility: Medical Toxicology Branch

**Review Stage:** includes the review of the final draft of the Risk Characterization Document within DRP and externally by OEHHA, US EPA and other interested parties. Also includes development of DPR response to reviewers comments.

**Approval Stage:** completed Risk Characterization Document awaiting approval by Assistant Director.

**Inactive :** No current risk assessment activities because of higher priorities.

### **Active Ingredients**

1. *Acephate- Approval stage*
2. *Acrolein – Hazard identification and exposure assessment stages*
3. *Carbaryl– Risk Characterization stage*
4. *Chloropicrin – Approved by the Scientific Review Panel, listed as TAC, Review stage for occupational*

*Changes from previous Report #51 (7/16/2009) are in italics*

\* new active ingredient

## RISK ASSESSMENT PRIORITIZATION LIST

Report # 52

July 15, 2011

5. *Chlorothalonil – Risk characterization stage*
6. *Chlorpyrifos – Hazard identification stage, concurrent with USEPA*
7. *Cyfluthrin – Hazard identification and exposure assessment stages*
8. *Diazinon – Hazard identification and exposure assessment stages*
9. 1,3-dichloropropene (Telone) – Risk characterization stage
10. *Dicofol – Hazard identification stage, voluntary cancellation at USEPA*
11. Esfenvalerate – Hazard identification stage, inactive
12. Fipronil - Hazard identification and exposure assessment stages
13. Indoxacarb– Hazard identification and exposure assessment stages
14. *Methomyl – Hazard identification stage and exposure assessment stages*
15. *Methyl parathion –Approval stage*
16. *Paradichlorobenzene – Hazard identification stage and exposure assessment stages*
17. Paraquat - Inactive
18. Phosphine – Hazard identification and exposure assessment stages
19. Propargite – Risk characterization stage
20. Propyzamide – Inactive.
21. Simazine - Hazard identification and exposure assessment stages
22. *Sodium tetrathiocarbonate - Hazard identification and exposure assessment stages, voluntary cancellation at USEPA*

*Changes from previous Report #51 (7/16/2009) are in italics*

\* new active ingredient